(¿Â¶óÀÎ&¿ÀÇÁ¶óÀÎ) 2020³â Á¦72Â÷ ´ëÇÑÇǺΰúÇÐȸ Ãß°èÇмú´ëȸ : 2020-10-17±³À°ÀÏÀÚ : 2020-10-17
±³À°Àå¼Ò : ¿Â¶óÀÎ&¿ÀÇÁ¶óÀÎ µ¿½Ã °³ÃÖ (¿ÀÇÁ¶óÀÎ: ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ 2Ãþ ÇѶóȦ ¿Ü)
±³À°ÁÖÁ¦ :
(¿Â¶óÀÎ&¿ÀÇÁ¶óÀÎ) 2020³â Á¦72Â÷ ´ëÇÑÇǺΰúÇÐȸ Ãß°èÇмú´ëȸ ÁÖÃÖ±â°ü : ´ëÇÑÇǺΰúÇÐȸ
´ã´çÀÚ : ¼´ëÇå
¿¬¶ôó : 02-3473-0284
À̸ÞÀÏ :
kda@derma.or.kr ±³À°Á¾·ù : ÇǺΰú
Âü¼®¿¹»óÀοø : 800¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 25 ½Ã°£ 25ºÐ
¼¼ºÎ¼ö°·á : 500,000¿ø
ºñ°í ¿ÀÇÁ¶óÀÎ Á¤È¸¿ø 70,000 ÁØȸ¿ø 30,000 / ¿Â¶óÀÎ Á¤È¸¿ø 50,000 ÁØȸ¿ø20,000 ¸¸65¼¼ ÀÌ»ó ¸éÁ¦ ºñȸ¿ø 500,000
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 10¿ù 17ÀÏ ÇѶó 1+2 13:15~13:20 Introduction Chair()
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 1+2 13:20~13:35 Future of Dermatologist in 4th Industrial Revolution ¾È°Ç¿µ(û´ã°í¿î¼¼»ó ´ÚÅÍÁöÇǺΰú)
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 1+2 14:00~14:25 Biologics ³ªÁ¤ÀÓ(¼¿ïÀÇ´ë)
Åä·Ð 10¿ù 17ÀÏ ÇѶó 1+2 14:25~14:30 Q&A ()
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 1+2 14:30~14:55 New dermatologic drugs and drug candidates ¹èÁ¤¹Î(°¡Å縯ÀÇ´ë)
Åä·Ð 10¿ù 17ÀÏ ÇѶó 1+2 14:55~15:00 Q&A ()
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 2 15:30~15:40 Initial Presentation for Pros ÇãâÈÆ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 2 15:40~15:50 Initial Presentation for Cons ±èÀÏȯ(°í·ÁÀÇ´ë)
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 2 15:50~15:55 Rebuttal by Pros ÇãâÈÆ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 2 15:55~16:00 Rebuttal by Cons ±èÀÏȯ(°í·ÁÀÇ´ë)
±âŸ 10¿ù 17ÀÏ ¹éµÎ 2 16:00~16:10 Discussion with audience ()
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 2 16:10~16:20 Initial Presentation for Pros ¹Ú°æÈÆ(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 2 16:20~16:30 Initial Presentation for Cons ÇÑÅ¿µ(À»ÁöÀÇ´ë)
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 2 16:30~16:35 Rebuttal by Pros ¹Ú°æÈÆ(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 2 16:35~16:40 Rebuttal by Cons ÇÑÅ¿µ(À»ÁöÀÇ´ë)
±âŸ 10¿ù 17ÀÏ ¹éµÎ 2 16:40~16:50 Discussion with audience ()
±âŸ 10¿ù 17ÀÏ ÇѶó 3 17:00~17:05 Introduction ()
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 17:05~17:16 Cutaneous lupus erythematosus °íÁÖ¿¬(ÇѾçÀÇ´ë)
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 17:16~17:27 Chronic urticaria ¹ÚÀºÁÖ(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 17:27~17:38 Mycosis fungoides ±èÀ¯Âù(¾ÆÁÖÀÇ´ë)
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 17:38~17:49 Rosacea and sensitive skin ÀÌÁ¾Èñ(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 17:49~18:00 Chronic hand and foot eczema À̵¿ÈÆ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 1 14:00~14:15 Pain in skin diseases ±èÁ¤Àº(ÇѾçÀÇ´ë)
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 1 14:15~14:35 Treatment of postherpetic neuralgia ±èµÎȯ(¿ï»êÀÇ´ë ¸¶ÃëÅëÁõÀÇÇаú)
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 1 14:35~14:50 How to deal with pain during dermatosurgery º¯Áö¿ø(ÀÎÇÏÀÇ´ë)
Åä·Ð 10¿ù 17ÀÏ ¹éµÎ 1 14:50~15:00 Q&A ()
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 1 15:30~15:50 Pemphigus (PV & PF) ±èÁ¾ÈÆ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 1 15:50~16:10 Atypical pemphigus (PNP, IgA pemphigus, pemphigus herpetiformis, pemphigus vegetans) ±è¼öÂù(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 1 16:10~16:30 Bullous pemphigoid, MMP, LAD, HG ³ëÁÖ¿µ(°¡ÃµÀÇ´ë)
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 1 16:30~16:50 Epidermolysis bullosa acquisita, Dermatitis herpetiformis ÀÌÁö¹ü(Àü³²ÀÇ´ë)
Åä·Ð 10¿ù 17ÀÏ ¹éµÎ 1 16:50~17:00 Q&A ()
±âŸ 10¿ù 17ÀÏ ¹éµÎ 1 17:30~17:32 Introduction Chair()
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 1 17:32~17:48 Seborrheic dermatitis and mimickers ±èµ¿Çö(Â÷ÀÇ´ë)
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 1 17:48~18:04 Folliculitis and common diseases masquerading as folliculitis À¯¹Ú¸°(°æÈñÀÇ´ë)
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 1 18:04~18:20 Practical use of dermoscopy on scalp diseases ±è¹®¹ü(ºÎ»êÀÇ´ë)
Åä·Ð 10¿ù 17ÀÏ ¹éµÎ 1 18:20~18:30 Q&A ()
±âŸ 10¿ù 17ÀÏ ¹éµÎ 2 17:40~17:43 Introduction Chair()
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 2 17:43~17:58 The way to precision medicine for alopecia Á¶¼ºÁø(¼¿ïÀÇ´ë)
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 2 17:58~18:13 A move toward precision medicine in melanoma treatment by next generation sequencing ÀÌ¿µº¹(°¡Å縯ÀÇ´ë)
Åä·Ð 10¿ù 17ÀÏ ¹éµÎ 2 18:13~18:20 Q&A ()
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 1+2 15:30~15:35 Introduction ()
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 1+2 15:35~16:20 Common skin disease in animals Ȳö¿ë(¼¿ï´ë ¼öÀÇ´ë)
Åä·Ð 10¿ù 17ÀÏ ÇѶó 1+2 16:20~16:30 Q&A ()
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 1 17:00~17:03 Introduction Chair()
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 1 17:03~17:25 What you need to know about ingrown nails (22min) ¹ÚÇö¼±(¼¿ïÀÇ´ë)
Åä·Ð 10¿ù 17ÀÏ ¹éµÎ 1 17:25~17:30 Q&A ()
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 1+2 16:30~16:55 New approach to acne scar treatment for beginners ÃÖõÇÊ(´ëÇÑÇǺΰúÀÇ»çȸ Á¤º¸ÀÌ»ç/ÇϴôÀ³¦ÇǺΰú)
Åä·Ð 10¿ù 17ÀÏ ÇѶó 1+2 16:55~17:00 Q&A ()
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 1+2 17:00~17:25 My clinical approach to the sensitive skin ±èÀ¯Á¤(´ëÇÑÇǺΰúÀÇ»çȸ ÇмúÀÌ»ç/±¤¸í»õÇϾáÇǺΰú)
Åä·Ð 10¿ù 17ÀÏ ÇѶó 1+2 17:25~17:30 Q&A ()
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 1+2 17:30~17:55 The absorbable thread lifting. Where are we up to now? ±èâ½Ä(´ëÇÑÇǺΰúÀÇ»çȸ ±³À°ÀÌ»ç/âÇǺΰú)
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 1+2 17:55~18:00 Q&A ()
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 1+2 13:35~13:40 Introduction ()
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 1+2 13:40~13:55 Epidemiologic Study for Herpes Zoster ¹Ú¿µ¹Î(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 1+2 13:55~14:00 Q&A ()
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 09:15~09:18 Introduction ()
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 09:18~09:33 The roles of aryl hydrocarbon receptor and autophagy in skin immune system and skin barrier function Á¤º¸¿µ(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 09:33~09:48 Drug screening system development with high-throughput sequencing targeting skin-specific T cells in atopic dermatitis ¹Úâ¿í(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 09:48~10:03 Application of Modified ¡°Omics¡± Research platform using Exosomes (Àϸí A.M.O.R.E. ¿¬±¸) ÇÑÇüÁø(°Ç¾çÀÇ´ë)
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 10:03~10:15 Q&A ()
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 1 09:00~09:15 Overview and introduction of board examination ()
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 1 09:15~09:40 Keratinization, barrier development and skin immune system ±è¹Ì¸®(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 1 09:40~10:05 Atopic dermatitis, contact dermatitis, seborrheic dermatitis and other eczematous dermatitis À±Çö¼±(¼¿ïÀÇ´ë)
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 1 10:05~10:10 Break ()
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 1 10:10~10:35 Papulosquamous disease ÃÖÀçÀº(À»ÁöÀÇ´ë)
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 1 10:35~10:55 Bacterial and fungal infection Á¤ÀÇÇö(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 1 10:55~11:15 Viral and other infection ¹Úº´Ã¶(´Ü±¹ÀÇ´ë)
ÈÞ½Ä 10¿ù 17ÀÏ ¹éµÎ 1 11:15~11:20 Break ()
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 1 11:20~11:35 Mucosal and adnexal disease ÀÌ»óÀº(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 1 11:35~12:00 Dermatopathology ¹ÚÁöÇý(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 2 09:00~09:10 Overview & Importance ±èÀÏȯ(°í·ÁÀÇ´ë)
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 2 09:10~09:30 Current Devices – Usages, Pros and Cons ¼ÛÇØÁØ(°í·ÁÀÇ´ë)
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 2 09:30~09:50 Melanocytic skin lesions vs Melanoma ¹®Á¦È£(¼¿ïÀÇ´ë)
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 2 09:50~10:10 NMSC – Basal cell carcinoma ±è¹®¹ü(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 2 10:10~10:30 NMSC - Actinic keratosis, Bowen, SCC, etc ±èÁØ¿µ(°æºÏÀÇ´ë)
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 2 10:30~10:50 Benign skin tumors -SK, DF, Eccrine poroma, Vascular tumors etc ±èÈñÁÖ(°¡ÃµÀÇ´ë)
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 2 10:50~11:10 Nail disorders - melanonychia, melanoma À̵¿À±(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 2 11:10~11:30 Nevus – Congenital, Aquried, Blue nevus ÀÌ°©¼®(Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 1+2 08:00~08:03 Introduction ()
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 1+2 08:03~08:48 How to Increase Quality of Line for Psoriasis Patients? ±èűÕ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 1+2 08:48~09:00 Q&A ()
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 1+2 11:30~11:33 Introduction ()
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 1+2 11:33~12:18 A common misconception when choosing biologics for psoriatic patients ±èµ¿Çö(Â÷ÀÇ´ë)
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 1+2 12:18~12:30 Q&A ()
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 2 14:00~14:03 Introduction ()
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 2 14:03~14:48 Completely clear skin that lasts with rapidly visible results: Real World Evidence in Korean patients with moderate to severe psoriasis ±èº´¼ö(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 2 14:48~15:00 Q&A ()
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 2 16:50~16:53 Introduction ()
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 2 16:53~17:13 Updateon dupilumab clinical data in adults and adolescents with moderate-to-severeAD ¼¿µÁØ(Ãæ³²ÀÇ´ë)
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 2 17:13~17:33 Koreanreal-world experience with dupilumab ÇÑÅ¿µ(À»ÁöÀÇ´ë)
±³À°½Ã°£ 10¿ù 17ÀÏ ¹éµÎ 2 17:33~17:40 Q&A ()
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 14:00~14:05 Overview chair()
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 14:05~14:20 Curettage ¿Àº´È£(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 14:20~14:35 Cryotherapy ÀÌ°©¼®(Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 14:35~14:50 Intralesional injection ÃÖÁö¿õ(¾ÆÁÖÀÇ´ë)
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 14:50~15:00 Q&A ()
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 15:30~15:35 Overview chair()
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 15:35~15:45 Diagnosis of hyperpigmentation and hypopigmentation Dermoscopic pattern identification in hyperpigmentary disorders Á¤º¸¿µ(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 15:45~16:00 Differential diagnosis for hypopigmentary disorders ÃÖÁ¾¿ø(Ãæ³²ÀÇ´ë)
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 16:00~16:10 Treatment of vitiligo Treatment approaches for vitiligo and maintenance treatment ½ÅÁ¤Çö(ÀÎÇÏÀÇ´ë)
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 16:10~16:20 Surgical approaches for vitiligo ¹èÁ¤¹Î(ÈúÇϿ콺ÇǺΰú)
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 16:20~16:30 Treatment of dyspigmentation Underlying mechanism of idiopathic guttate hypomelanosis and its treatment modalities ¿À»óÈ£(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 16:30~16:40 Treatment of refractory melasma: How we do it and what¡¯s new? ÃÖõÇÊ(ÇϴôÀ³¦ÇǺΰú)
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 16:40~16:50 How to handle mottled hypopigmentation laser toning? ÀÌÇØ¿õ(·çÀ̽ºÇǺΰú)
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 16:50~17:00 Q&A ()
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 09:00~09:05 Overview chair()
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 09:05~09:20 Effective treatment for acne and acne scar with EBD °íÁÖ¿¬(ÇѾçÀÇ´ë)
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 09:20~09:35 Wrinkles and Skin textures: Dermal Rejuvenation using EBD ±¸º»Ã¶(³ªÀ½ÇǺΰú)
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 09:35~09:50 Simple at a glance but tough inside: How to improve enlarged pores with EBD Aged pores, Widening pores with sebaceous hyperactivity, and Others À¯ÈÁ¤(°í·ÁÀÇ´ë)
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 09:50~10:00 Case Discussion and Q&A From Floor °íÁÖ¿¬±¸º»Ã¶À¯ÈÁ¤()
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 17:30~17:35 Overview ÃÖ±¤¼º(ÀÎÇÏÀÇ´ë)
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 17:35~17:50 Topical treatment update ÀÌ»óÈÆ(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 17:50~18:05 The update of 5 alpha reductase inhibitors use À¯¹Ú¸°(°æÈñÀÇ´ë)
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 18:05~18:20 Device and emerging treatment ÇãâÈÆ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 10¿ù 17ÀÏ ÇѶó 3 18:20~18:30 Q&A ()